Anavex Life Sciences

AVXL XNAS BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Market Cap

260M

Short interest (May 15)

20.8%

Net Short (Jun 03 ): 0.0%

Borrow Fee

0.72%

↓ 53.7%

Available Shares

900K

↓ 26.9%

Price Chart

Company Overview

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

Company Info

Exchange: NASDAQ
Industry: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CIK: 0001314052
Asset Type: CS

Market Data

Market Cap: $258,090,846
Employees: 34
Status: Active

Short Interest

Current Borrow Fee 0.72%
Range: 0.71% - 1.01%
Available Shares 900K
Range: 60K - 850K

Recent Changes

Fee Change: ↑ 3.7%
Available Change: ↓ 2.9%

Quick Actions

View Dilution Chart
Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam Unsubscribe anytime